Trial Profile
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 08 Oct 2013 Planned number of patients changed from 177 to 252 as reported by European Clinical Trials Database record.
- 20 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD 2010).
- 28 Jun 2010 Results were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).